

Positive decision about a Chinese ICORES® patent

The Chinese Patent Agency has announced the intention to grant a patent regarding Iconovo's inhalation device, ICORES. Iconovo has previously granted patents in Sweden, Europe (ERPO) and Japan. The new patent covers the technology used in many of Iconovo's projects like generic Symbicort®.

"China is an enormous market and this patent gives us protection of a very important and fundamental function in ICORES. To have a granted patent in China is crucial when doing business development. This additional patent strengthens our international intellectual property and increases the value of our product portfolio", says Johan Wäborg, CEO.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

[Positive decision about a Chinese ICORES® patent](#)